Please assess the completion status of the following clinical trial:

Trial Title: Patient-Reported Effectiveness and Safety of Etoricoxib in Osteoarthritis (OA)(0663-113)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must Be Over 20 Years Of Age, Regardless Of Sex~* Must Have A Diagnosis Of OA That Requiring Treatment~* Patients Must Have Taken an NSAID, Cox-2 Or Opioids On The Majority Of Days During The Last 4 Weeks Before Enrollment Who Are Intolerant (Due To Gastrointestinal Adverse Events) Or Inadequately Respond To Current Therapy (Vas \>= 40 mm On A Pain Scale From 0-100 mm)~* Excluding Osteoarthritis, The Patient Is Judged To Be In Otherwise General Good Health Based On Medical History, Physical Examination, And Routine Laboratory Tests~* Must Agree To Participate Voluntarily In The Study~* Must Have The Capacity To Understand And Answer The Questionnaires Used In The Study~* Must Agree To Return For A Follow-Up Visit With The Treating Physician Four Weeks After The Initiation Of Treatment With Etoricoxib~* Patient Is Willing To Sign Informed Consent Form~Exclusion Criteria:~* Under 20 Years Of Age~* Severe Hepatic Insufficiency (Child-Pugh Score \> 9)~* Advanced Renal Insufficiency (Creatinine Clearance \< 30 Ml/Min)~* Any Contraindication Or Warning Or Precaution As Mentioned In The Approved Study Drug Package Insert~* Gi Ulcer With Active Bleeding Present At Study Enrollment~* Patient Has A Recent History Of Stroke, Myocardial Infarction Or Transient Ischemic Attack (Within The Previous 2 Years)

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Etoricoxib

Based on this trial design, predict the completion outcome and termination type (if applicable).